MedPath

Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells

Completed
Conditions
HEMATOLOGIC MALIGNANCIES
Registration Number
NCT00770523
Lead Sponsor
Cooperative Study Group A for Hematology
Brief Summary

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.

Detailed Description

Primary end points are treatment-related mortality and engraftment. Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria

-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing.

Exclusion Criteria
  • Patients should not have major illness or organ failure
  • Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.
  • Patients must not be pregnant or lactating.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
treatment-related mortality and engraftmentall cause mortality
Secondary Outcome Measures
NameTimeMethod
regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.Time point(s) at which outcome measure is assessed.

Trial Locations

Locations (1)

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath